2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919) Anthelmintic, pre- and postharvest fungicide, also freq. for vet. use. Used as a postharvest treatment for bananas, plantains and oranges. Registered in Canada for control of silver scurf in stored potatoes Thiabendazole is a fungicide and parasiticide. Thiabendazole is also a chelating agent, which means that it is used medicinally to bind metals in cases of metal poisoning, such as lead poisoning, mercury poisoning or antimony poisoning. Thiabendazole is vermicidal and/or vermifugal against Ascaris lumbricoides ('common roundworm'), Strongyloides stercoralis (threadworm), Necator americanus, Ancylostoma duodenale (hookworm), Trichuris trichiura (whipworm), Ancylostoma braziliense (dog and cat hookworm), Toxocara canis, Toxocara cati (ascarids), and Enterobius vermicularis (pinworm). Thiabendazole also suppresses egg and/or larval production and may inhibit the subsequent development of those eggs or larvae which are passed in the feces.
Thiabendazole is a fungicide and parasiticide. It is used primarily to control mold, blight, and other fungally caused diseases in fruits (e.g. oranges) and vegetables; it is also used as a prophylactic treatment for Dutch elm disease. As an antiparasitic, it is able to control roundworms (such as those causing strongyloidiasis), hookworms, and other helminth species which attack wild animals, livestock and humans.
Top Gene Interactions
Hepatic. Metabolized almost completely to the 5-hydroxy form which appears in the urine as glucuronide or sulfate conjugates. Route of Elimination: It is metabolized almost completely to the 5-hydroxy form which appears in the urine as glucuronide or sulfate conjugates. Half Life: The half-life for thiabendazole in both normal and anephric patients is 1.2 hours (range 0.9 to 2 hours). The half-life for the 5-hydroxythiabendazole metabolite in both normal and anephric patients is 1.7 hours (range 1.4 to 2 hours).
For the treatment of strongyloidiasis (threadworm), cutaneous larva migrans (creeping eruption), visceral larva migrans, and trichinosis.
- Route of Exposure:
Rapidly absorbed and peak plasma concentration is reached within 1 to 2 hours after the oral administration of a suspension. Some systemic absorption may occur from topical preparations applied to the skin.
- Carcinogenicity: No indication of carcinogenicity to humans (not listed by IARC).
- Toxicity: The oral LD 50 is 3.6 g/kg, 3.1 g/kg and 3.8 g/kg in the mouse, rat, and rabbit respectively.
Mechanism of Action
|Target Name||Mechanism of Action||References|
Aryl hydrocarbon receptor
Cytochrome P450 2B6
Cytochrome P450 1A1
Peptidyl-prolyl cis-trans isomerase FKBP1A
Cytochrome P450 1A2
Methionine aminopeptidase 2
Cytochrome P450 2C9
Multidrug and toxin extrusion protein 1
Urokinase plasminogen activator surface receptor
C-X-C motif chemokine 10
Aurora kinase A
Cytochrome P450 1B1
Tyrosine-protein kinase JAK2
Methionine aminopeptidase 1
Thiabendazole Interacts with Diseases
|Disease||Inference Score||References/Inference Genes|
|Diabetes Mellitus, Experimental||15.45|
|Drug-induced liver injury||13.56|
|Diabetes Mellitus, Type 2||11.87|
|Myocardial Reperfusion Injury||10.33|
|Amyotrophic lateral sclerosis||10.0||